Glenmark Pharma has received final USFDA approval to market a generic version of AstraZeneca’s Nexium, used to treat acid reflux. The drug esomeprazole magnesium delayed-release will be marketed in in the strengths of 20 mg and 40 mg. The approved products are a generic version of AstraZeneca Pharmaceuticals’ Nexium delayed-release capsules. According to market estimates, the product has sales of around $395.1 million in the 12-month period ended March 2019.
Company Profile : Glenmark Pharma Ltd